Observational studyCancer medicine2026
Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionClinical characteristics and outcomes of patients treated for dedifferentiated liposarcoma (DDLPS) at community oncology centers are not well studied. Our goal was to assess real-world patterns of diagnosis, clinical management, and outcomes of patients with DDLPS in US community settings.
methodsThis was a retrospective observational study of electronic health records (EHRs) obtained from the iKnowMed EHR system for patients diagnosed with DDLPS between January 1, 2008, and October 31, 2023, within The US Oncology Network and non-Network practices. The primary outcomes were real-world overall survival (rwOS) from diagnosis and from the start of the first systemic therapy after documented metastatic disease (1L[M]) until death (due to any cause). Real-world progression-free survival (rwPFS) was assessed from 1L(M) systemic therapy initiation to the earliest date of progression or date of death (due to any cause).
resultsA total of 123 patients with DDLPS (women, 33.3%; White, 60.2%; metastatic disease, 34.0%) were included. Biomarker testing was most frequently performed for the MDM2 proto-oncogene (78.0%), followed by CDK4 (38.2%) and TP53 (10.6%). DDLPS treatments included surgery (76.0%), radiation therapy (35.0%), and systemic agents (46.3%), of which cytotoxic drugs, particularly first-line anthracycline, were the most common. Median rwOS was 44.2 months. For patients with metastatic disease, median rwPFS was 2.7 months, and rwOS from start of 1L(M) systemic therapy was 11.7 months.
conclusionPatients with DDLPS treated in US community settings are heterogeneous in terms of demographic and clinical characteristics, biomarker testing, treatment, and outcomes. The relatively poor survival rates suggest an unmet need for better therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.